White paper urges FDA to act against companies producing counterfeit GLP-1s
New Standards of Care offer ‘tailor-made recommendations’ for treating obesity
Patients navigate an ‘absolutely insane’ maze to afford weight-loss drugs
Tirzepatide bests semaglutide for weight loss in adults with obesity
Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
New weight loss pill could benefit people with Type 2 diabetes: Eli Lilly
Amy Schumer on switching weight-loss medications
Microdosing weight-loss drugs goes viral, and worries experts
Read at Bloomberg (subscription required)
NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain
Zepbound users discuss weight loss after preliminary research touts effectiveness
Watch the video at ABC News
Weight-loss drugs compared
Watch at ABCNews
As many as 1 in 5 people won’t lose weight with GLP-1s, experts say
Read at the Associated Press
Semaglutide 2.4 mg reduces all-cause hospital admissions
Read at Medscape
Is microdosing Ozempic safe?
Read at Everyday Health
Why people are breaking open their Mounjaro pens
Read at The Atlantic
Doctors Wish More People Over 65 Took Ozempic
Doctors wish more older patients would give obesity medicines a shot Medications that help people manage their weight could have extra advantages for people 65
Some diabetes drugs like Ozempic may lower risks of 10 cancers, study finds
Read at Medical News Today
Tirzepatide led to greater real-world weight loss than semaglutide for adults with obesity
Read at Healio
Ozempic v. Mounjaro? There’s a clear winner for weight loss, study finds.
Read at USA Today
Novel GLP-1/Glucagon drug promising for weight loss
Read at MSN
